logo

For the Inventor, By the Inventor

Loughborough, United Kingdom

Anthony Howard Ingall

This inventor holds 18 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Chemical Compounds. Top assignees: Astrazeneca Ab, Astra Pharmaceuticals Limited, Astra Zeneca U.k. Limited. Active years: 1980-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony Howard Ingall. Retrieved from https://idiyas.com/inventor/anthony-howard-ingall

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 72.2


Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 214(Granted Patents)


Location History:

  • Leicestershire, GB (1997)
  • Leicestersire, GB (2005)
  • Loughborough, GB (1980 - 2008)
  • Minehead, GB (2017)

Company Filing History:

goldMedal8 out of 1,535 
 
Astrazeneca Ab
 patents
silverMedal4 out of 24 
 
Astra Pharmaceuticals Limited
 patents
bronzeMedal3 out of 110 
 
Astra Zeneca U.k. Limited
 patents
4. 3 out of 313 
 
Fisons Ltd.
 patents

Years Active: 1980-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Triazolo Compounds
Thienopyrimidinedinones
Autoimmune Disease
Platelet Aggregation
P2T Receptor Antagonists
N-Alkyl ATP Analogues
Chemical Modulation
Inhibitors
Phenylsulfinyl Compounds
Benzimidazoles
Benzopyrans
Compositions
18 patents (USPTO):Explore Patents
1. RE46276 - Triazolo(4,5-D)pyrimidine compounds (2017-01-16),
2. 7393854 - Thienopyrimidinedinones and their use in modulation of autoimmune disease (2008-07-01),
3. 7384950 - Thienopyrimidinediones and their use in the modulation of autoimmune disease (2008-06-10),
4. 7361660 - Chemical compounds (2008-04-22),
5. 7250419 - Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition (2007-07-31),
6. 7064126 - Compounds (2006-06-20),
7. 6974868 - Compounds (2005-12-13),
8. 6890923 - Compounds (2005-05-10),
9. 6525060 - Triazolo(4,5-d)pyrimidine compounds (2003-02-25),
10. 6297232 - Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments (2001-10-02),
11. 6251910 - 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists (2001-06-26),
12. 5955447 - N-alkyl-2-substituted ATP analogues for treatment of embolic disease (1999-09-21),
13. 5747496 - Inhibitors of platelet aggregation (1998-05-05),
14. 5721219 - N-alkyl-2-substituted ATP analogues and administration to inhibit (1998-02-24),
15. 5654285 - ADP and ATP analogues, process for making and administration to inhibit (1997-08-05),

Title: **Anthony Howard Ingall: Innovator in Medicinal Chemistry**

Introduction

Anthony Howard Ingall, a prominent inventor based in Loughborough, GB, has made significant contributions to the field of medicinal chemistry. With an impressive portfolio consisting of 18 patents, Ingall's work primarily revolves around innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest inventions, Ingall has developed the **Triazolo(4,5-D)pyrimidine compounds**. These compounds, along with their applications as medicaments, promise substantial advances in therapeutic practices. The formula for these compounds is defined precisely in the specifications, showcasing the depth of his research.

Another notable patent features **Thienopyrimidinedinones**, which are intended for the modulation of autoimmune diseases. This invention describes the compounds of formula (I) and outlines the processes for their preparation, as well as the formulation of pharmaceutical compositions that capitalize on their therapeutic potential.

Career Highlights

Ingall has worked with renowned companies, including **AstraZeneca AB** and **Astra Pharmaceuticals Limited**, where he has applied his expertise to advance innovative therapies. His extensive experience in the pharmaceutical industry has equipped him with the knowledge necessary to drive significant developments in drug formulation and medicinal applications.

Collaborations

Throughout his career, Ingall collaborated with notable professionals in the field, including **Simon David Guile** and **Paul Andrew Willis**. These collaborations have facilitated the exchange of ideas and refined approaches in medicinal chemistry, contributing to the successful development of their shared projects.

Conclusion

In summary, Anthony Howard Ingall stands out as a leading inventor in the realm of medicinal chemistry. His ongoing commitment to innovation is evidenced by his extensive patent portfolio, which continues to shape the future of therapeutic treatments. Ingall's work exemplifies the crucial role of inventors in enhancing healthcare solutions through groundbreaking research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…